Learn more about eLife assessments Blood flow to the brain is a sensitive marker of neuronal activity as well as of a number of diseases, including stroke, tumours and neurodegenerative conditions.

DeFi protocols distributed 15% of their fees in 2025, as the sector shifted to sharing its revenues with token holders.

Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the last patient has ...

SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially ...

UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing*First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and ...

Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease December 9, 2025 4:15 ...

Some 2,000 oranges are picked Friday in annual harvest from the surviving tree that launched the citrus boom. Columnist David ...

Q3 2025 Earnings Call Transcript December 8, 2025 Operator: Ladies and gentlemen, good day, and welcome to Yuanbao Inc.’s Third Quarter 2025 Earnings Conference Call. Today’s conference is being ...

Partnership positions MaxYield™ as a core AI engine for next-generation smart rings and consumer cardiac monitoring into the broader INTRINSICA platform.

SCOTTSDALE, AZ / ACCESS Newswire / December 14, 2025 / Infinity Chem, operating through its website at today announced the formal launch of its U.S-manufactured peptide program, built around domestic ...

UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing* First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK ...